Sutro Biopharma, Inc - STRO Company Short-Term Debt

Sutro Biopharma (STRO) - corporate logo

The short-term debt trend for Sutro Biopharma, Inc. (STRO) reflects the impact of strategic alliances for the development of oncology drugs, with the 0.00 mark indicating the current state of liabilities. Business stability is based on unique cell-free protein synthesis and a strong team of immuno-oncologists, who are actively recruiting specialized managers for the final stages of clinical trials.

STRO: sutrobio.com Short-Term Debt 07/04/2022 - 10/29/2026

STRO (Sutro Biopharma, Inc): analytical breakdowns and indicator data

- price and consensus price forecast:
Price Chart Sutro Biopharma|STRO - Average Forecast Price
- market capitalization data:
Market Value Sutro Biopharma, Inc.|STRO - Total Company Value
- book capitalization data:
Net Assets per Single Share Sutro Biopharma|STRO - Total Stockholders' Equity|Market Capitalization to Book Value Ratio sutrobio.com|STRO - Company Balance Sheet Assets
- debt and liquidity data:
Total Debt to Equity Ratio Sutro Biopharma, Inc.|STRO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Sutro Biopharma, Inc.|STRO - Aggregate Debt Obligations|Debts to Book Capitalization Sutro Biopharma, Inc.|STRO - Long-Term Debt Volume|Company Short-Term Debt Sutro Biopharma
Analysis of all company metrics:Sutro Biopharma STRO
Finished products of sutrobio.com

This indicator captures total liabilities with maturities of up to one year, allowing for an assessment of current liquidity and the refinancing risk of operating expenses. By analyzing short-term debt volume, an investor can track the debt load dynamics, which for Sutro Biopharma, Inc. (STRO) are directly linked to the maintenance costs of its high-tech cell-free synthesis plant and automated climate control systems in California.

Competitor analysis for Sutro Biopharma, Inc.

IBRX (ImmunityBio) - Company Short-Term Debt|IMCR: Short-Term Debt|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt ZYME (Zymeworks Inc.)|Short-Term Debt tangotx.com|IOVA: Company Short-Term Debts|Short-Term Indebtedness Immatics NV IMTX|XNCR: Company Current Liabilities|CMPX - Short-Term Debt|Company Current Liabilities Replimune Group, Inc. (REPL)|LYEL - Company Short-Term Loans and Borrowings|Innate Pharma - Company Short-Term Debts|PYXS (Pyxis Oncology) - Short-Term Debt Volume|Company Short-Term Debt CGEN|Company Current Liabilities IOBT|Company Short-Term Debt INKT (MiNK Therapeutics, Inc.)|Company Current Liabilities werewolftx.com HOWL|Company Current Liabilities IMMX (Immix Biopharma)|alxoncology.com - Company Short-Term Debts|Cue Biopharma (CUE) - Company Short-Term Debt|PDSB: Company Short-Term Indebtedness|Company Short-Term Debt SONN|Short-Term Debt MAIABiotech.com|Liminatus Pharma LLC - Company Current Liabilities|Short-Term Indebtedness Lava Tx (LVTX)|Company Current Liabilities NextCure Corp|Amount of Current Liabilities leaptx.com (LPTX)|Company Short-Term Debts Intensity Therapeutics, Inc.|Company Short-Term Loans and Borrowings Sensei Biotherapeutics Inc SNSE|TOVX (Theriva Biologics) - Company Short-Term Debts|GRTS: Short-Term Debt|Company Short-Term Debt Kineta Bio KA|NexImmune Corporation (NEXI) - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts VCNX|HARP - Company Short-Term Debt